UNLOXCYT® An Evolution in Checkpoint Inhibition: A Balanced Approach for Patients With Advanced CSCC

This program will provide an overview of the CSCC landscape, focusing on UNLOXCYT® (cosibelimab-ipdl), a checkpoint inhibitor for the treatment of locally advanced and metastatic CSCC that is not amenable to curative surgery or curative radiation.